Latest Zelmac Trial Focuses On 12 Mg Dose In Women; Drug Is "Approvable"

Novartis' latest trial for the irritable bowel syndrome agent Zelmac focuses on a 12 mg daily dosing regimen in 1,500 females, with results to be submitted to FDA by the end of the year.